2013
DOI: 10.1111/bph.12024
|View full text |Cite
|
Sign up to set email alerts
|

(E)‐2,4‐bis(p‐hydroxyphenyl)‐2‐butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK‐mediated suppression of NF‐κB and up‐regulation of TNFRSF10B (DR5)

Abstract: BACKGROUND AND PURPOSEThe Maillard Reaction Products (MRPs) are known to be effective in chemoprevention. Here we focused on the anticancer effects of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal (a MRP) on human non-small-cell lung cancer (NSCLC) cells and its mechanism of action. EXPERIMENTAL APPROACHWe analysed the activity of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal on NSCLC cells (NCI-H460 and A549) by use of Western blot analysis for major apoptotic proteins, MAPK, NF-kB and death receptor expression. We also us… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
20
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
7

Relationship

5
2

Authors

Journals

citations
Cited by 22 publications
(21 citation statements)
references
References 48 publications
0
20
0
Order By: Relevance
“…Our other previous studies demonstrated that a higher expression of DR6 and lower activity of NF-κB in (E)-2,4-bis(p-hydroxyphenyl)-2-butenal Cell growths are mean ± SD of three experiments. *P < 0.05 indicates statistically significant differences from control cells treated colon cancer cells (Ban et al 2014), and a higher expression of DR5 and lower activity of NF-κB in (E)-2,4-bis(p-hydroxyphenyl)-2-butenal treated lung cancer cells (Kollipara et al 2013). Higher expression of DR3 and DR5 and lower activity of NF-κB were also found in the SVT-treated xenograft tumor tissues.…”
Section: Discussionmentioning
confidence: 89%
“…Our other previous studies demonstrated that a higher expression of DR6 and lower activity of NF-κB in (E)-2,4-bis(p-hydroxyphenyl)-2-butenal Cell growths are mean ± SD of three experiments. *P < 0.05 indicates statistically significant differences from control cells treated colon cancer cells (Ban et al 2014), and a higher expression of DR5 and lower activity of NF-κB in (E)-2,4-bis(p-hydroxyphenyl)-2-butenal treated lung cancer cells (Kollipara et al 2013). Higher expression of DR3 and DR5 and lower activity of NF-κB were also found in the SVT-treated xenograft tumor tissues.…”
Section: Discussionmentioning
confidence: 89%
“…NF‐κB is negatively mediated by p38 MAPK under certain conditions, and it is an important regulatory protein involved in the invasion and proliferation of many cancer cells . We therefore examined whether the observed Na v 1.7‐mediated inhibition of p38 activation resulted in upregulation of MACC1 expression by NF‐κB.…”
Section: Resultsmentioning
confidence: 99%
“…We previously identified BHPB, a tyrosine-fructose MR product as a STAT3 inhibitor, which has potential therapeutic properties against multiple diseases including RA15161718192021222333. Despite its multiple pharmacological properties, the major drawback of BHPB in drug development is its lack of drug-likeness properties and limited chemical stability.…”
Section: Discussionmentioning
confidence: 99%
“…This action mediates the potent therapeutic effects of BHPB against RA14 as well as Alzheimer’s disease151617, and tumour growth181920212223. However, its drug-likeness is not relevant for drug development because it has a low chemical stability, low solubility, and high toxicity.…”
mentioning
confidence: 99%